Marker Therapeutics, Inc. (MRKR) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Marker Therapeutics, Inc. (MRKR) closed at USD 0.89 on 2026-10-14, a change of -11.9 % over the past year, with a market capitalization of USD 15.34M.

Marker Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Marker Therapeutics, Inc. key figures

Previous close

USD 0.89 (2026-10-14)

1-year change

-11.9 %

Market cap

USD 15.34M

Enterprise value

USD 4.01M

P/E ratio (trailing)

-2.19

P/E ratio (forward)

-1.74

EPS (trailing)

-0.42

EPS (forward)

-0.53

PEG ratio

n/a

Price to book

1.26

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

2.51

Employees

5

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Marker Therapeutics, Inc. and compare it with other stocks.